Group Reporting Changes

Dr. Martens PLC

07 October 2026

 

7 October 2026

DR. MARTENS PLC ("the Company" and, together with its subsidiaries, "the Group")

Group Reporting Changes and Re-presentation of Historical Financial Data

In our FY26 results on 19 May 2026, we announced that in FY27 we would move to market-based reporting, and no longer report on a regional basis, in line with the new operating model for the business. To aid investor understanding, we are today publishing historical financial data in the new reporting structure.

Change in reportable segments

The Group has revised its reportable segments under IFRS 8 'Operating Segments' to better reflect the way the management team reviews performance, allocates resources and executes the strategy.

Effective from 1 April 2026, the Group now has two reportable segments: (1) "US" and, (2) "Global Markets (ex US)". Corporate overhead and functional costs are not allocated to these two segments and are presented separately within "Central" as an unallocated reconciling item.

Impact and re-presentation of financial data

To facilitate meaningful comparison with future reporting periods, historical comparative information has been re-presented to reflect this revised reporting structure.

The re-presentation affects only the allocation and presentation of financial information between the Group's reportable segments and unallocated Central costs. It has no impact on the Group's previously reported consolidated revenue, gross margin, profit before tax, consolidated statement of financial position or earnings per share (EPS).

From a channel perspective, we will disclose DTC:B2B revenue mix at a Group level. We are also enhancing our disclosure to include Demand Generating Spend at a Group level going forward, to aid understanding of operating costs (historic figures are included in the table below). 

FY25 and FY26 re-presented historical information

	H1 FY26					H2 FY26					FY26
	US	Global Markets (ex US)	Central	Total		US	Global Markets (ex US)	Central	Total		US	Global Markets (ex US)	Central	Total
	£m	£m	£m	£m		£m	£m	£m	£m		£m	£m	£m	£m
Revenue	107.6	214.4	-	322.0		151.0	291.9	-	442.9		258.6	506.3	-	764.9
Gross margin	62.7	147.6	-	210.3		95.4	200.3	-	295.7		158.1	347.9	-	506.0
Adjusted EBIT	16.8	61.7	(75.4)	3.1		43.7	100.8	(68.3)	76.2		60.5	162.5	(143.7)	79.3
EBIT	15.8	61.2	(75.5)	1.5		43.3	98.5	(86.3)	55.5		59.1	159.7	(161.8)	57.0
Adjusted profit/(Loss) before tax	15.8	60.2	(85.4)	(9.4)		42.6	99.4	(77.6)	64.4		58.4	159.6	(163.0)	55.0
Profit/(Loss) before tax	14.8	59.7	(85.5)	(11.0)		42.2	97.1	(95.6)	43.7		57.0	156.8	(181.1)	32.7
Demand generating spend				(22.4)					(33.9)					(56.3)

	H1 FY25					H2 FY25					FY25
	US	Global Markets (ex US)	Central	Total		US	Global Markets (ex US)	Central	Total		US	Global Markets (ex US)	Central	Total
	£m	£m	£m	£m		£m	£m	£m	£m		£m	£m	£m	£m
Revenue	106.2	218.4	-	324.6		164.1	298.9	-	463.0		270.3	517.3	-	787.6
Gross margin	63.1	144.6	-	207.7		96.8	207.2	-	304.0		159.9	351.8	-	511.7
Adjusted EBIT	13.6	58.4	(75.0)	(3.0)		41.0	101.1	(78.4)	63.7		54.6	159.5	(153.4)	60.7
EBIT	12.3	58.4	(85.8)	(15.1)		40.2	98.9	(87.0)	52.1		52.5	157.3	(172.8)	37.0
Adjusted Profit/(Loss) before tax	12.5	56.8	(85.9)	(16.6)		40.0	99.5	(88.8)	50.7		52.5	156.3	(174.7)	34.1
Profit/(Loss) before tax	11.2	56.8	(96.7)	(28.7)		39.2	97.3	(99.0)	37.5		50.4	154.1	(195.7)	8.8
Demand generating spend				(20.0)					(36.5)					(56.5)

		FY26				FY25
Revenue by market £m		H1	H2	FY26		H1	H2	FY25
US		107.6	151.0	258.6		106.2	164.1	270.3
Global Markets (ex US)		214.4	291.9	506.3		218.4	298.9	517.3
UK		53.4	82.1	135.5		56.3	85.8	142.1
DACH		34.3	53.2	87.5		35.2	51.4	86.6
Japan		20.2	26.9	47.1		20.2	29.5	49.7
Other Managed Markets		90.7	116.6	207.3		90.1	120.0	210.1
Partner Markets		15.8	13.1	28.9		16.6	12.2	28.8
Total		322.0	442.9	764.9		324.6	463.0	787.6

Other reporting changes

The Group has re-categorised Mules from Sandals to Shoes, which will have the impact of reducing the previously disclosed Sandals revenue. The impact on FY26 is c.4%pts shift in revenue mix from sandals into shoes.

Ends

Investors and analysts:                                                                    

Bethany Barnes, Director of Investor Relations & Corporate Communications

[e-mail]  

[phone]                                                                                                                                                

Press enquiries:

Rob Greening / Ludo Baynham-Herd / Oliver Banks

[e-mail]
[phone]

Notes to editors

ABOUT DR. MARTENS 

Dr. Martens is an iconic British footwear brand founded in Northamptonshire, England. Its first silhouette, the 1460 boot - named after the date it was produced - rolled off the production line on 1 April 1960. Stitched into its heel loop were three words in the founder's own handwriting, a nod to the boot's new air-cushioned sole: With Bouncing Soles. Originally chosen by workers for their comfort and durability, "Doc's" or "DM's" boots and shoes were later adopted by musicians and subcultural pioneers who took them from the street to the global stage. 

Over six decades later, Dr. Martens operates in more than 60 countries and employs around 3,600 people. The company continues to honour the brand's heritage through its 'Made in England' footwear, manufactured at its original Northamptonshire factory, while meeting global demand from multiple high-quality production sites across Asia. All our products are made with an unwavering commitment to craft, combined with innovative techniques. 

Those same three words are now the brand's enduring global platform. With Bouncing Soles is not a tagline or a seasonal campaign; it is a statement of intent and a creative thread that runs through everything Dr. Martens does, from product and retail to partnerships and community. What began as a promise of comfort has become an opportunity for reflection and a call to action: What Makes Your Sole Bounce?  

It celebrates the individuality, creativity and self-expression of a global community glorious in its differences, united by a yellow thread. 

A brand built to put a bounce in the step of those who stand out from the crowd, Dr. Martens is available through Direct-to-Consumer (Retail and Ecommerce) and Wholesale channels. The brand's collections span its original silhouettes, including The Icons such as the 1460 boot, 1461 shoe, 2976 Chelsea boot and Adrian loafer, as well as newer franchises including the Zebzag, Buzz and Lowell. The lineup also includes an extensive range of sandals, a dedicated Kids collection, and a curated selection of bags, small leather goods, and accessories. Every Dr. Martens collection reflects craftsmanship, heritage, timeless style, comfort, and versatility. Having transcended generations, the brand remains as relevant today as it was at its inception. Its signature yellow welt stitching, grooved sole edges, and scripted "With Bouncing Soles" heel loops remain iconic symbols recognised around the world. 

Dr. Martens plc (DOCS.L) is listed on the main market of the London Stock Exchange and is a constituent of the FTSE 250 index. 

For more information, visit www.drmartens.com or http://www.drmartensplc.com 

 

END